David C. Kaslow
No más puestos en curso
Historial de carrera de David C. Kaslow
Antiguos cargos conocidos de David C. Kaslow.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Bank of America Private Bank
 Bank of America Private Bank Investment ManagersFinance A subsidiary of Bank of America Corp. (NYSE: BAC), Boston-based Bank of America Private Bank (BAPB) offers private banking and wealth management services. | Gestor de Cartera-Acciones | - | 20/09/2005 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/02/1999 | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | 01/10/2001 | - |
Formación de David C. Kaslow.
| The University of California, San Francisco | Doctorate Degree |
| University of California, Davis | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Portfolio Manager-Equities | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Bank of America Private Bank
Bank of America Private Bank Investment ManagersFinance A subsidiary of Bank of America Corp. (NYSE: BAC), Boston-based Bank of America Private Bank (BAPB) offers private banking and wealth management services. | Finance |
- Bolsa de valores
- Insiders
- David C. Kaslow
- Experiencia
